EU-wide position versus national implementation — what changed since

EU-wide position versus national implementation — what changed since Writing it up because I had to work it out twice and would rather nobody else did.

A coverage question with the paperwork detail included, since that is what determines the answer.

Denial received, with a stated reason. My reading of the reason is that it tells me exactly what to submit next, which is the useful thing about a well-written denial.

Before I spend a week on it: is my reading of the stated criterion correct, and is there a documented precedent for this specific ground?

the opening post answers the question as asked. The question underneath it is different.

Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.

EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.

Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation.

Worth separating two things that the opening post runs together.

Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.

post #5 is right about the mechanism and I think understates the practical bit.

Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.

On post #5 — agreed on the reasoning, with one qualification.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

Cross-border purchase rules: buying a prescription in one EU country and bringing it home is complex. The substance is legal but crossing borders with it requires understanding both countries' import rules.

post #10 is right about the mechanism and I think understates the practical bit.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

Worth separating two things that post #8 runs together.

France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.

Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.

Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.